Radiopharm Theranostics Limited American Depositary Shares (NASDAQ:RADX) — Stock Price
Radiopharm Theranostics Limited American Depositary Shares (NASDAQ:RADX) is currently trading at $2.80 USD, up 0.00% today. Over the past 52 weeks, shares have ranged between $2.78 and $4.68. This page tracks Radiopharm Theranostics Limited American Depositary Shares's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see RADX company net worth.
Radiopharm Theranostics Limited American Depositary Shares (RADX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Radiopharm Theranostics Limited American Depositary Shares's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Radiopharm Theranostics Limited American Depositary Shares Income Statement — Revenue, Profit & Earnings by Year
Radiopharm Theranostics Limited American Depositary Shares's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $3.63 Million | $299.23K | $292.36K | $8.83K |
| Cost of Revenue | $3.59 Million | $0.00 | $0.00 | — |
| Gross Profit | $39.28K | $299.23K | $292.36K | $8.83K |
| Research & Development | $27.52 Million | $17.56 Million | $13.80 Million | $4.12 Million |
| SG&A | $16.53 Million | $15.22 Million | $13.02 Million | $10.85 Million |
| Total Operating Expenses | $38.21 Million | $36.92 Million | $34.80 Million | $19.93 Million |
| Operating Income | $-38.17 Million | $-36.62 Million | $-34.51 Million | $-19.92 Million |
| EBITDA | $-38.17 Million | $-44.08 Million | $-31.19 Million | $-17.96 Million |
| EBIT | $-38.17 Million | $-47.21 Million | $-34.49 Million | $-20.94 Million |
| Interest Expense | $65.30K | $642.89K | $86.09K | $9.35 Million |
| Income Before Tax | $-38.24 Million | $-47.85 Million | $-34.57 Million | $-30.29 Million |
| Income Tax Expense | $103.29K | $96.36K | $38.01K | $44.40K |
| Net Income | $-38.34 Million | $-47.95 Million | $-34.61 Million | $-30.34 Million |
Radiopharm Theranostics Limited American Depositary Shares Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Radiopharm Theranostics Limited American Depositary Shares's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $86.48 Million | $72.04 Million | $74.95 Million | $83.38 Million |
| Total Current Assets | $39.85 Million | $22.85 Million | $16.30 Million | $27.26 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | $10.40 Million | $987.41K | $4.47 Million | $56.48K |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $43.61 Million | $44.68 Million | $29.37 Million | $20.42 Million |
| Total Current Liabilities | $14.93 Million | $17.58 Million | $13.23 Million | $7.88 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | $-29.12 Million | $-18.58 Million | $-11.70 Million | $-26.98 Million |
| Total Stockholder Equity | $44.79 Million | $28.12 Million | $44.38 Million | $62.96 Million |
| Retained Earnings | $-145.73 Million | $-111.34 Million | $-65.35 Million | $-30.82 Million |
Radiopharm Theranostics Limited American Depositary Shares Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Radiopharm Theranostics Limited American Depositary Shares generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-36.65 Million | $-22.98 Million | $-23.20 Million | $-9.92 Million |
| Capital Expenditures | $0.00 | $0.00 | $1.53 Million | $28.34 Million |
| Free Cash Flow | $-36.65 Million | $-22.98 Million | $-24.73 Million | $-38.25 Million |
| Investing Cash Flow | $1.77 Million | $-320.00K | $-1.53 Million | $-28.37 Million |
| Financing Cash Flow | $45.43 Million | $30.20 Million | $9.22 Million | $65.11 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | — | — | — | — |
| Depreciation | — | — | — | — |
| Change in Cash | $10.54 Million | $6.88 Million | $-15.28 Million | $26.95 Million |
Radiopharm Theranostics Limited American Depositary Shares Earnings History — EPS Actual vs. Analyst Estimates
Track Radiopharm Theranostics Limited American Depositary Shares's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 26, 2026 | 0.00 | 0.00 | — |
| Dec 03, 2025 | -2.10 | 0.00 | — |
| Sep 16, 2025 | -0.01 | 0.00 | — |
| May 28, 2025 | -1.96 | 0.00 | — |
| Feb 28, 2025 | -0.01 | 0.00 | — |